Evidence map›Paper›PMID 31554925›Full record

ArticleScientific reports2019

Over-expression of miR-34c leads to early-life visceral fat accumulation and insulin resistance.

Philip H Jones, Brian Deng, Jessica Winkler, Arin L Zirnheld, Sarah Ehringer, Vikranth Shetty, Matthew Cox, Huy Nguyen, Wen-Jun Shen, Ting-Ting Huang and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Philip H JonesAdvanced Genomic Technology, LLC, Louisville, KY, USA.
Brian DengPalo Alto Veterans Institute for Research, Palo Alto, CA, USA.
Jessica WinklerAdvanced Genomic Technology, LLC, Louisville, KY, USA.
Arin L ZirnheldAdvanced Genomic Technology, LLC, Louisville, KY, USA.
Sarah EhringerAdvanced Genomic Technology, LLC, Louisville, KY, USA.
Vikranth ShettyAdvanced Genomic Technology, LLC, Louisville, KY, USA.
Matthew CoxAdvanced Genomic Technology, LLC, Louisville, KY, USA.
Huy NguyenDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.
Wen-Jun ShenDepartment of Endocrinology, Stanford University School of Medicine, Stanford, CA, USA.
Ting-Ting HuangDepartment of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA. tthuang@stanford.edu.ORCID http://orcid.org/0000-0002-6332-7241
Eugenia WangAdvanced Genomic Technology, LLC, Louisville, KY, USA.
Advanced Genomic Technology (United States) · USVA Palo Alto Health Care System · USPalo Alto Veterans Institute for Research · USStanford University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Overweight children and adolescents are at high risk for adult and late life obesity. This report investigates some underlying mechanisms contributing to obesity during early life in an animal model. We generated a strain of transgenic mice, cU2, overexpressing human microRNA 34c, a microRNA functionally implicated in adipogenesis. Male and female cU2 mice exhibit significant weight gain, accompanied by marked increase in abdominal fat mass and metabolic abnormalities, including reduction of both glucose clearance rate and insulin sensitivity, as early as two months of age. Adipogenesis derailment at this early age is suggested by decreased expression of adiponectin, the fat mass and obesity-associated gene, and the adiponectin receptor R1, coupled with a reduction of the brown fat biomarker PAT2 and the adipogenesis inhibitor SIRT1. Notably, adiponectin is an important adipokine and an essential regulator of glucose and fatty acid homeostasis. cU2 mice may provide a crucial animal model for investigating the role of miR-34c in early onset insulin resistance and visceral fat mass increase, contributing to accelerated body weight gain and metabolic disorders. Intervention in this dysregulation may open a new preventive strategy to control early-life weight gain and abnormal insulin resistance, and thus prevalent adult and late life obesity.

Indexed as

AnimalsDisease Models, AnimalFemaleGlucoseInsulin ResistanceIntra-Abdominal FatMaleMetabolic Clearance RateMice, TransgenicMicroRNAsOverweightGlucoseMicroRNAsMIRN34 microRNA, human

Identifiers

PMID31554925
PMCPMC6761099
OpenAlexW2975079093

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.